​​

October 29, 2024 - Additional claims are granted for US Patent 15997743 to support additional oncological treatment discoveries. -  https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12129272

​

August 1, 2024 - University of Tennessee Health Science Center announces in an unpublished study, that experimental drug candidate, ANV221, performs superior to trastuzumab in patient-derived, Her2-positive breast cancer animal models in well-tolerated dosages. 

​​

Jan 2024 - California Life Science FAST accelerator recognizes Anviron for its 2024 cohort.  

 

October 26, 2023 - United States Patent is granted for Anviron's ANV322, "DPAGT1 inhibitors of capuramycin analogues and their antimigratory activities of solid tumors". - https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20230340006

​​

September 5th, 2023 - Anviron initiates study of ANV221 & ANV322 in combination with trastuzumab in HER2+, drug-resistant breast cancers. 

​

August 23, 2023 - Jing Yang, PhD joins Anviron board of advisors. Dr. Yang is a Professor of Pharmacology at the UC San Diego and specializes in breast cancers and drivers of invasion and metastasis. - https://pharmacology.ucsd.edu/faculty/department-faculty/jing-yang.html

​

August 18, 2023 - Japan Patent is granted for Anviron's ANV221, "Glycosyl Transferase Inhibitors For Treatment Of Solid Tumors". - Japanese Patent No.: 7334183

​

July 17, 2023 - The Journal of Clinical Investigation publishes a large, multi-university breast cancer study that established the link between DPAGT1 and drug resistance in HER2+ breast cancer.  DPAGT1 inhibition reversed drug resistance and significantly shrank tumors in HER2+ breast cancers. Anviron launch candidates named in the study. - https://www.jci.org/articles/view/164428

​

June 2, 2023 - Orange County Business Journal names Anviron Co-founder to the OC50, acknowledging the top innovators in the Southern California region. - https://www.ocbj.com/special-report/oc-50/2023-bradley-morrison/ 

​

Mar 7, 2023 - United States Patent for Anviron's ANV221 is granted for Anviron's "Glycosyltransferase inhibitors for the treatment of solid tumors." -  https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11597743

​

Dec 5, 2022 - ANV221, FDA Orphan Drug candidate for the treatment of Pancreatic Cancer is featured in Orange County Business Journal - https://www.ocbj.com/start-ups-2/startups-innovations-201/

​

Nov 17-18, 2022 - Anviron Founder participates in invitation-only, Born in California, a University of California innovation event. "California produces more startups every year than any other state. ” said Matt Hanson, Ph.D., director of New Ventures at Applied Innovation. “Many of those companies — in fact, many Fortune 500 companies and unicorns — were founded by University of California alumni. The Born in California demo days is an important and valuable event for bringing our founders and funders together to launch and grow companies that can put a dent in the universe.”

​

​​

​​

​​

​​

​

​

​

​

​

​

​

​

​

Jul 25, 2022 - Physician, researcher and pioneer oncologist Jack Singer M.D. joins Anviron Board of Advisors. Dr. Singer is former Chief of Medical Oncology with the Seattle VA hospital where he piloted what would become the marrow transplante program of the entire VA system, an important procedure in restoring patient bone marrow after cytotoxic chemotherapy. As founder and Chief Science Officer of Cell Therapeutics, Dr. Singer was responsible for drug discovery including several IND, and NDA applications for oncology candidates. Dr. Singer is a Professor of Oncology at Washington State University, College of Medicine.

​

Jan 5, 2022 - University of Tennessee Health Science Center announce in unpublished study that experimental drug candidate, ANV221, demonstrates equivalence to paclitaxel in triple-negative breast cancer animal models and significantly reduces EGF gene activity.  

​

Oct 12, 2021 - The United States Food and Drug Administration (FDA) has granted “Orphan Drug Designation” to our drug candidate ANV221 for the treatment of pancreatic cancers.  This important milestone confers the benefit of seven (7) years of market exclusivity in the United States and validates the team’s hard work toward developing a promising therapy for this difficult-to-treat disease.

​

Mar 18, 2021 - UTRF, UTHSC, and Anviron Partner to Commercialize Novel Treatment for Pancreatic Cancer - The University of Tennessee Research Foundation, the University of Tennessee Health Science Center and biotech therapeutics startup Anviron recently announced a partnership to commercialize a novel product candidate with promising efficacy against pancreatic cancer tumors.

​

Dec 28, 2020 - University of Tennessee Research Foundation & Anviron announce agreement to an exclusive, world-wide license to commercialize a novel low toxicity DPAGT-1 inhibitor with demonstrated in vivo efficacy against pancreatic cancer tumors.

​

Oct 27, 2020 - University of California San Diego Innovator Spotlight, Bradley Morrison Founder